← Back to Search

Other

Sodium Pyruvate for Coronavirus

Phase 2 & 3
Waitlist Available
Research Sponsored by Cellular Sciences, inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 0, 2, 4, 6, 8, 10, 12, and 14
Awards & highlights

Study Summary

This study is evaluating whether inhaled sodium pyruvate may help reduce inflammation and symptoms in patients with chronic obstructive pulmonary disease (COPD).

Eligible Conditions
  • Coronavirus
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 0, 2, 4, 6, 8, 10, 12, and 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 0, 2, 4, 6, 8, 10, 12, and 14 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evaluate the Ability of Inhaled Nasal Sodium Pyruvate to Affect SaO2 in COVID-19 Infected Patients.
Evaluate the Ability of Inhaled Nasal Sodium Pyruvate to Change COVID-19 Viral Titers.
Secondary outcome measures
Sodium
Evaluate the Ability of Inhaled Nasal Sodium Pyruvate to Affect Chills in COVID-19 Infected Patients.
Evaluate the Ability of Inhaled Nasal Sodium Pyruvate to Affect Congestions in COVID-19 Infected Patients.
+6 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment of COVID-19 infected patients with a sodium pyruvate nasal sprayExperimental Treatment1 Intervention
In this arm, patients will be provided with N115 sodium pyruvate nasal spray and instructed to use it 3x daily for 14 days. This group will be compared to the placebo control group to determine if sodium pyruvate reduces the symptoms, duration and replication of COVID-19 infection.
Group II: Placebo control treatment of COVID-19 infected patientsPlacebo Group1 Intervention
In this arm, patients will be provided with a saline nasal spray as a placebo control. Patients will use the saline nasal spray 3x daily for 14 days, similar to the sodium pyruvate drug arm. This will serve as a control for the symptoms, duration and replication of COVID-19 infection.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pyruvic acid
FDA approved

Find a Location

Who is running the clinical trial?

Family First Medical Research CenterUNKNOWN
2 Previous Clinical Trials
72 Total Patients Enrolled
Cellular Sciences, inc.Lead Sponsor
5 Previous Clinical Trials
217 Total Patients Enrolled
Missouri State UniversityOTHER
3 Previous Clinical Trials
173 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection
2021. "Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04824365.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top